The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mixed methods study of the feasibility and acceptability of remote monitoring of lung cancer patient-reported outcomes.
 
Gita N Mody
Stock and Other Ownership Interests - Pfizer
Honoraria - Elsevier
Research Funding - SIVAN Innovation (Inst)
 
Chaely Medley
Honoraria - G1 Therapeutics
Consulting or Advisory Role - G1 Therapeutics
Expert Testimony - G1 Therapeutics
 
Allison Mary Deal
No Relationships to Disclose
 
Jared Weiss
Stock and Other Ownership Interests - Achilles Therapeutics (I); Enfuego Therapeutics; Lyell Immunopharma; Nektar; Nuvalent, Inc.; Vertex; Vesselon
Consulting or Advisory Role - abbvie; AstraZeneca; BeiGene; EMD Serono; G1 Therapeutics; Genentech; Genmab; Jounce Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Chad Victor Pecot
Leadership - EnFuego Therapeutics, Inc
Stock and Other Ownership Interests - EnFuego Therapeutics
Consulting or Advisory Role - Medscape
Research Funding - Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Methods and Compositions for Ligand delivery of oligonucleotides; Methods and compositions using RNA Interference for inhibition of KRAS (Inst); Methods and Compositions using RNA Interference for inhibition of MYC and dual KRAS/MYC targeting
Other Relationship - Enfuego Therapeutics
 
Carrie B. Lee
No Relationships to Disclose
 
Amanda Gentry
No Relationships to Disclose
 
Meghan C. O'Leary
No Relationships to Disclose
 
Sachita Shrestha
No Relationships to Disclose
 
Hemda Chen
Employment - SIVAN Innovation; TrueMed, LTD
Leadership - SIVAN Innovation
 
Lara Novak
No Relationships to Disclose
 
Ashley Weiner
Consulting or Advisory Role - EmpNia; Varian Medical Systems
 
Shetal Arvind Patel
Consulting or Advisory Role - Astellas Pharma; IQvia
Research Funding - Amgen (Inst); BeiGene (Inst); Dracen (Inst); Genentech/Roche (Inst); Macrogenics (Inst); Seagen (Inst); Shattuck Labs (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Angela M. Stover
Honoraria - Association of Community Cancer Centers (ACCC); Henry Ford Health System; Pfizer; Purchaser Business Group on Health
Consulting or Advisory Role - Navigating Cancer
Research Funding - Pfizer (Inst); SIVAN Innovation (Inst); Urogen pharma (Inst)